Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040222 · ClinicalTrials.gov registry record
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 377
- Enrollment target
NCT00040222: Completed study, sponsored by National Cancer Institute (NCI).
NCT00040222 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 377 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040222 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 377 participants
- Enrollment target
Study Summary
Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrella family studies protocol (78-C-0039). Cancer outcomes are documented through review of medical, vital, and pathology records. Selected individuals and family members are asked to complete questionnaires to assess etiologic risk factors and to undergo clinical evaluations specifically tailored to the relevant familial syndrome. Study participants are monitored prospectively for the development of outcomes of interest, typically by means of periodic mail or telephone contact. In selected instances, subjects may return to the Clinical Center periodically for study-specific follow-up examinations. Study participants are asked to donate biologic specimens to be used in the laboratory search for cancer etiology and mechanisms of carcinogenesis. DNA and serial serum samples will be collected. Tumor tissue will be obtained whenever feasible. Clinical genetic testing for tumor susceptibility gene(s) mutations and risk notification will be offered consistent with ASCO guidelines when reasonable individual cancer risk estimates can be delivered, and only to those participants who choose to know their individual genetic status after appropriate education and counseling. The testing will be conducted exclusively in Clinical Laboratory Improvement Amendments (CLIA)-licensed laboratories. Clinical genetic testing and risk notification are entirely optional and do not affect subject eligibility for other aspects of the protocol. A separate consent procedure and consent form will be used for genetic testing and risk notification. This protocol, developed in response to recommendations developed by the Clinical Center IRB, is intended to: 1. Provide a mechanism under which the Clinical Genetics Branch can honor the commitment made to the
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2002-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040222
The ClinicalTrials.gov registry entry for NCT00040222 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00040222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040222 about?
NCT00040222 is a clinical study titled "Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer". Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study, which is a syndrome-specific sub-set of the long-standing DCEG Human Genetics Program umbrella family studies protocol (78-C-0039). Cancer outcome...
What is the current status of trial NCT00040222?
This trial is currently completed. The enrollment target is 377 participants. The study started on 2002-07-01.
Who is sponsoring clinical trial NCT00040222?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.